tPA is the only FDA approved drug for stroke treatment, but the narrow time window and the risk for hemorrhage limited its clinical use; however, a TCM compound called T541, which consist of Astragalus saponins, salvianolic acids, and PNS, injected together with tPA could attenuate hemorrhage and angioedema caused by tPA, mainly because that T541 could increase BBB integrity and upregulate energy metabolism, thus increasing the fibrinolytic ability and extended the time window for tPA (Chen et al., 2018b). The gene discussed is PLAT; the disease is Stroke.